CorMedix CRMD Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares at other companies

Lesaka Technologies, Inc.LSAK

2.6M-8.4%

WSFS FinancialWSFS

0-100%

Flagstar Bank FLG

5.7M-39.3%

WaFd, Inc.WAFD

827.8K-1.8%

MSCIMSCI

577K+63.9%

CorMedixCRMD

1.6M+432%

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares.

The official record: CorMedix’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's sharebased compensation arrangement by sharebased payment award options nonvested number of shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's sharebased compensation arrangement by sharebased payment award options nonvested number of shares?: CorMedix (CRMD) reported sharebased compensation arrangement by sharebased payment award options nonvested number of shares of 1.6M in Q4 2025.
What does sharebased compensation arrangement by sharebased payment award options nonvested number of shares mean?: This represents the total number of stock options or equity awards granted to employees and directors that have not yet vested. It serves as a measure of future potential dilution and the company's commitment to long-term incentive compensation. Tracking this helps investors model the impact of future share issuance on earnings per share.